Role of PET-CT in staging esophageal cancer: a practical guide

Esophageal cancer is uncommon in Australia, with around 1,500 new cases diagnosed annually and a five-year survival rate that still sits below 20 percent. Most patients present with locally advanced disease, and the choice between neoadjuvant therapy, primary surgery, or definitive chemoradiation rests on accurate staging. For clinicians working across public cancer centres in Sydney, Melbourne, Brisbane, Perth and Adelaide, getting that staging right the first time avoids weeks of treatment delay and unnecessary morbidity.

PET-CT combines the functional information of positron emission tomography with the anatomical detail of low-dose CT, allowing detection of disease that conventional imaging misses. This guide outlines the practical role of PET-CT in staging esophageal cancer, with attention to how the test is funded, accessed and integrated into multidisciplinary care across Australia.

The aim is to give surgeons, oncologists, gastroenterologists and nuclear medicine physicians a shared framework for requesting and interpreting these scans alongside the staging protocols published by Cancer Australia and the ANZ Society of Nuclear Medicine.

Understanding how PET-CT works

PET-CT uses an intravenous injection of 18F-fluorodeoxyglucose (FDG), which accumulates in cells with high metabolic activity. Most malignant tissue shows intense uptake, while normal structures show low background. The CT component provides anatomical landmarks and attenuation correction, allowing metabolic hotspots to be localised to the esophageal wall, regional nodes, liver, lungs or skeleton.

Acquisition takes 20 to 40 minutes, with the patient fasting four to six hours beforehand. Serum glucose above roughly 10 mmol/L degrades image quality and warrants rescheduling. Standard coverage from skull base to mid-thigh suits the typical spread patterns of upper and mid esophageal tumours.

Why PET-CT changes staging decisions

The single most important contribution of PET-CT is detecting distant metastases invisible on contrast-enhanced CT. Australian data, including work from Peter MacCallum Cancer Centre in Melbourne, suggests upstaging in 15 to 20 percent of patients from resectable to incurable disease. Skipping this step risks sending patients to major surgery only to discover peritoneal or bone metastases afterwards.

PET-CT also carries prognostic value. High SUVmax in the primary correlates with poorer survival, and interval PET after neoadjuvant therapy can inform whether to continue or modify the planned operative approach.

PET-CT versus CT, EUS and MRI

No single modality answers every staging question. Endoscopic ultrasound remains the most accurate tool for T-stage assessment and sampling of regional nodes, particularly for lower esophageal and gastroesophageal junction tumours. Contrast CT is reliable for evaluating the lungs and liver, while diffusion-weighted MRI is gaining ground for characterising equivocal liver and bone lesions.

The limitations of PET-CT include spatial resolution of only 5 to 7 mm and reliance on metabolic contrast. Small perigastric nodes and tiny peritoneal deposits can be missed, and FDG-avid inflammation from post-obstructive esophagitis or recent biopsy can mimic malignancy.

Reading the scan in everyday practice

Nuclear medicine reports typically describe the SUVmax of the primary, characterise FDG-avid nodes, and flag suspicious distant sites. An SUVmax above roughly 9 to 10 in the primary often signals aggressive biology, though thresholds vary. Equivocal findings, especially sub-centimetre pulmonary nodules or mildly avid liver lesions, should be correlated with dedicated contrast imaging rather than treated as definitive metastases.

Two pitfalls deserve emphasis. Physiological uptake in the gastric cardia can be mistaken for tumour extension, particularly during neoadjuvant therapy. FDG uptake in skeletal muscle, brown fat or urinary tract can also be misinterpreted by less experienced readers. Always review the images alongside the report and discuss uncertain findings directly with the nuclear medicine team.

Australian access, funding and logistics

In Australia, PET-CT for biopsy-proven esophageal cancer is funded through Medicare under MBS items such as 61523 for whole-body staging and 61529 for restaging after neoadjuvant therapy. The scan requires specialist referral and is available through public hospital nuclear medicine departments or accredited private providers with bulk-billing arrangements.

Access differs markedly by geography. Metropolitan Melbourne, Sydney and Brisbane typically offer waits of one to two weeks, while patients in rural Western Australia, the Northern Territory and western Queensland may travel significant distances. Telehealth multidisciplinary meetings now link specialists at centres such as Royal Darwin Hospital with metropolitan surgical and oncology teams, reducing the need for patients to relocate during staging.

Integrating PET-CT into multidisciplinary care

PET-CT findings only become useful when they reach the right people. Australian cancer centres hold weekly multidisciplinary team meetings where thoracic surgeons, medical oncologists, radiation oncologists, gastroenterologists, radiologists and nuclear medicine physicians review imaging together. PET-CT images should be loaded into the hospital PACS and presented alongside endoscopy, contrast CT and biopsy results.

For ongoing treatment planning, eviQ provides Australian consensus guidance on neoadjuvant chemoradiation, while Cancer Australia's Optimal Care Pathway for oesophageal cancer outlines expected timelines from diagnosis to first treatment. Embedding PET-CT within these frameworks turns a scan into a meaningful staging event.

The most concrete next step for any clinician managing a newly diagnosed esophageal cancer patient is to ensure PET-CT is requested and reviewed at the first multidisciplinary team meeting, alongside endoscopic ultrasound and contrast CT, before any treatment decision is finalised.